What the trial was testing
The trial enrolled 245 patients with schizophrenia. The study was sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
The new drug reduced symptom scores by 7.5 more points than placebo over 4 weeks.
The New England journal of medicine · 2020 · NCT02969382
These findings — that the new drug reduced psychotic symptom scores significantly more than placebo over 4 weeks — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 245 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with schizophrenia, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This early-stage research shows promise for a new type of antipsychotic that works through a different mechanism than current medications. This treatment is not yet FDA-approved — ask your doctor about clinical trials testing this drug or other available antipsychotic options for schizophrenia.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open schizophrenia trials
Uppsala Psychosis Cohort
A multimodal longitudinal study in early stage psychosis patients and individuals at high risk for psychosis. Healthy controls are included for baseline comparisons. The aim is to investigate disease mechanisms of psychotic disorders, specifically focusing on the synaptic pruning hypothesis.
Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies
Researchers propose in this project to evaluate predictive factors of non response. It is defined by the lack of symptomatic remission at month 3, for patients presenting a first episode of psychosis. It will be performed on objective markers taken from imagery techniques. The link between evolution of these markers and clinical measures will be studied.